The healthcare industry's outlook is promising this year, driven by advancements pharmaceuticals, the rise of digital biopharmaceutical sales, and an increasing demand for health insurance. In this context, value investors might consider buying strong undervalued healthcare stocks with strong upside potential: Merck & Co., Inc. (MRK), Pfizer Inc. (PFE), and The Cigna Group (CI).
The healthcare industry is flourishing, with pharma products attracting investors for their consistent profitability amid economic fluctuations due to steady demand. As the global population ages and disease prevalence rises, the need for effective modern medications and biopharma products surges. Global pharmaceutical revenues are set to grow at a 6.2% CAGR, reaching $1.47 trillion by 2028.
